Skip to main content

Table 1 Thirty-day mortality in Candida bloodstream infection. Univariate analysis

From: Impact of inappropriate antifungal therapy according to current susceptibility breakpoints on Candida bloodstream infection mortality, a retrospective analysis

 

Total, n = 149

30-d Survivors, n = 93

30-d Non-survivors n = 56

p-value

Demographics

 Female

78 (52.3)

50 (53.7)

28 (50)

0.65

 Age, median (IQR)

47 (32–58)

44 (30–55)

48 (35.5–61.5)

0.23

 Intensive care unit admission

37 (24.8)

15 (16.1)

22 (39.2)

< 0.001

 APACHE II n = 122, median (IQR)

18 (14–24)

16 (12–20)

23 (18.5–28.5)

< 0.001

 Severe sepsis

66 (44.3)

29 (31.1)

37 (66)

< 0.001

Comorbidities

 Hematologic neoplasia

45 (30.2)

22 (23.6)

23 (41)

0.025

 Solid neoplasia

26 (17.4)

17 (18.2)

9 (16)

0.73

 Cardiovascular

37 (24.8)

22 (23.6)

15 (26.7)

0.7

 Chronic kidney disease

18 (12)

10 (10.7)

8 (14.2)

0.52

 Cirrhosis

11 (7.3)

1 (1)

10 (17.8)

< 0.001

 Diabetes mellitus

19 (12.7)

12 (12.9)

7 (12.5)

0.94

 Intra-abdominal infection

62 (41.6)

45 (48.3)

17 (30.3)

0.031

 Neutropenia

34 (22.8)

16 (17.2)

18 (32.1)

0.035

 Cancer CT

38 (25.5)

18 (19.3)

20 (35.7)

0.026

 CA-BSI

27 (18.1)

22 (23.6)

5 (8.9)

0.024

 CVC

123 (82.5)

80 (86)

43 (76.7)

0.15

 Early CVC removal

73 /123 (59.3)

55/80 (68.7)

18 /43 (41.8)

0.004

 Total parenteral nutrition

49 (32.8)

36 (38.7)

13 (23.2)

0.034

 Empiric antifungal therapy

35 (23.8)

27 (29.6)

8 (14.3)

0.033

 Steroid use

40 (26.8)

20 (21.5)

20 (35.7)

0.08

 Time to antifungal therapy median (IQR)

2 (1–3)

2 (1–2)

2 (1–3)

0.165

Initial treatment

 Echinocandin

64 (42.9)

42 (45.1)

22 (39.1)

0.48

 Caspofungin

43 (28.8)

27 (29)

16 (28.5)

0.89

 Anidulafungin

21 (14.1)

15 (16.1)

6 (11.3)

0.4

 AmB-d

61 (40.9)

35 (37.6)

26 (46.4)

0.29

 Azoles

25 (16.7)

16 (17.2)

9 (16)

0.85

 Fluconazole

24 (16.1)

15 (16.1)

9 (16)

0.95

 Voriconazole

1 (0.6)

1 (1)

Definitive treatment

 Echinocandin

56 (37.5)

36 (38.7)

20 (35.7)

0.71

 Caspofungin

31 (20.8)

17 (18.2)

14 (25)

0.34

 Anidulafungin

25 (16.7)

19 (20.4)

6 (10.7)

0.23

 AmB-d

46 (30.8)

21 (22.5)

25 (44.6)

0.005

 Azoles

47 (31.5)

36 (38.7)

11 (19.6)

0.015

 Fluconazole

41 (27.5)

31 (33.3)

10 (17.8)

0.4

 Voriconazole

6 (4)

5 (5.3)

1 (1.8)

0.27

 Inappropriate initial antifungal treatment

13 (8.7)

9 (9.6)

4 (7.1)

0.59

 Inappropriate definitive antifungal treatment

8 (5.3)

6 (6.4)

2 (3.5)

0.36

 Inappropriate initial and/or definitive treatment

16 (10.7)

11 (11.8)

5 (8.9)

0.58

 Non-albicans CBSI

89 (59.7)

62 (66.6)

27 (48.2)

0.026

C. tropicalis

35 (24)

19 (20)

16 (29)

0.25

C. glabrata

28 (19)

19 (20.4)

9 (16)

0.5

C. parapsilosis

16 (10.7)

15 (16)

1 (1.8)

0.006

  1. IQR interquartile range, APACHE acute physiology and chronic health evaluation, CT chemotherapy, CA-BSI catheter associated blood stream infection, CVC central venous catheter, AmB-d amphotericin B-deoxycholate, CBSI candida blood stream infection